Susquehanna International Group, LLP Nektar Therapeutics Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Nektar Therapeutics stock. As of the latest transaction made, Susquehanna International Group, LLP holds 19,800 shares of NKTR stock, worth $16,632. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,800

Previous 64,928 69.5%

Holding current value

$16,632

Previous $80,000 68.75%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$0.9 - $1.83 $284,463 - $578,409	-316,071 Reduced 82.96%	64,928 $80,000
Q1 2024 May 07, 2024	BUY	$0.49 - $0.96 $146,894 - $287,793	299,785 Added 369.13%	380,999 $354,000
Q4 2023 Feb 14, 2024	SELL	$0.42 - $0.57 $24,874 - $33,758	-59,225 Reduced 42.17%	81,214 $45,000
Q3 2023 Nov 14, 2023	SELL	$0.51 - $1.05 $124,499 - $256,321	-244,116 Reduced 63.48%	140,439 $84,000
Q2 2023 Aug 11, 2023	BUY	$0.53 - $1.03 $115,240 - $223,958	217,435 Added 130.11%	384,555 $223,000
Q1 2023 May 16, 2023	BUY	$0.64 - $3.15 $78,343 - $385,597	122,412 Added 273.8%	167,120 $116,000
Q4 2022 Feb 14, 2023	SELL	$2.03 - $4.28 $224,392 - $473,102	-110,538 Reduced 71.2%	44,708 $101,000
Q3 2022 Nov 14, 2022	BUY	$3.04 - $5.14 $130,802 - $221,158	43,027 Added 38.34%	155,246 $497,000
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $59,624 - $116,051	18,809 Added 20.14%	112,219 $426,000
Q1 2022 May 16, 2022	SELL	$4.16 - $13.72 $582,050 - $1.92 Million	-139,916 Reduced 59.97%	93,410 $503,000
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $2.01 Million - $3.42 Million	185,744 Added 390.37%	233,326 $3.15 Million
Q3 2021 Nov 15, 2021	SELL	$13.07 - $18.84 $131,536 - $189,605	-10,064 Reduced 17.46%	47,582 $855,000
Q2 2021 Aug 11, 2021	BUY	$16.52 - $20.4 $275,685 - $340,435	16,688 Added 40.74%	57,646 $989,000
Q1 2021 May 17, 2021	SELL	$16.56 - $25.46 $2.67 Million - $4.11 Million	-161,354 Reduced 79.76%	40,958 $819,000
Q4 2020 Feb 16, 2021	BUY	$15.77 - $19.03 $994,219 - $1.2 Million	63,045 Added 45.27%	202,312 $3.44 Million
Q3 2020 Nov 16, 2020	SELL	$16.59 - $24.79 $1.28 Million - $1.91 Million	-76,991 Reduced 35.6%	139,267 $2.31 Million
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $805,284 - $1.12 Million	47,763 Added 28.35%	216,258 $5.01 Million
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $5.11 Million - $9.88 Million	-353,286 Reduced 67.71%	168,495 $3.01 Million
Q4 2019 Feb 14, 2020	SELL	$15.87 - $23.12 $3.7 Million - $5.4 Million	-233,354 Reduced 30.9%	521,781 $11.3 Million
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $3.25 Million - $6.97 Million	192,223 Added 34.15%	755,135 $13.8 Million
Q2 2019 Aug 16, 2019	BUY	$31.0 - $36.3 $1.21 Million - $1.41 Million	38,951 Added 7.43%	562,912 $20 Million
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $462,303 - $541,341	14,913 Added 2.93%	523,961 $18.6 Million
Q1 2019 May 15, 2019	BUY	$31.58 - $46.35 $354,801 - $520,742	11,235 Added 2.26%	509,048 $17.1 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $5.24 Million - $9.75 Million	172,099 Added 52.84%	497,813 $16.4 Million
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $12.8 Million - $18.8 Million	-275,199 Reduced 45.8%	325,714 $19.9 Million
Q2 2018 Aug 14, 2018	SELL	$46.25 - $104.45 $427,535 - $965,535	-9,244 Reduced 1.52%	600,913 $29.3 Million
Q1 2018 May 15, 2018	SELL	$57.4 - $108.44 $10.1 Million - $19 Million	-175,461 Reduced 22.33%	610,157 $64.8 Million
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $8.57 Million - $22.5 Million	372,373 Added 90.11%	785,618 $46.9 Million
Q3 2017 Nov 14, 2017	BUY	$17.79 - $24.0 $7.35 Million - $9.92 Million	413,245	413,245 $9.92 Million

Others Institutions Holding NKTR

# of Institutions

146

Shares Held

140M

Call Options Held

32.6K

Put Options Held

14.1K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $157M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Nektar Therapeutics Transaction History